KN069 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
KN069 does the opposite of tirzepatide at the GIP switch, in one molecule, and it also caused weight loss. Half of a dose is still in the body after 37 to 46 days, among the longest of any drug on this site.
Evidence grade for KN069: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
No first-hand reports gathered yet. That is a gap in what we have collected, not a finding that nothing has been reported.
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
KN069 is a test weight loss shot. One molecule switches on GLP-1 and blocks GIP. Tirzepatide switches both on. Yet both cause weight loss, and nobody knows why. It lasts a very long time in the body. It is not approved anywhere.
What people take it for
- Weight loss from a single long lasting dose.
- An option other than tirzepatide.
What studies in people showed
There is one first study, in 48 Chinese men with extra weight. A single 90 mg dose cut weight by 4.71 percent at day 7. On a dummy it was 0.41 percent. The effect lasted up to 133 days. Side effects were mostly mild stomach and bowel problems. Half the drug was still in the body after 37 to 46 days. Weight lost in the first week is mostly water and gut contents, not fat.
What people report
Reports, not study results
The good
- Side effects in the first study were mostly mild to moderate stomach and bowel problems.
The bad
- It stays in the body for weeks. If you react badly, there is no way to stop it quickly.
- Only 48 men have had it, and there is no long term data.
Where these come from: From the one human study on this page. We have not collected user reports on this one yet.
My bottom line
My opinion: a drug you cannot switch off for months, tested in 48 men, is not something to experiment with. Watch it. Do not take it.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals KN069 has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weightno headcount stated · 1 study
- Losing fat specificallyno headcount stated · 1 study
- Blood sugar and insulinno headcount stated · 1 study
33 of the 36 indexed goals have no study of any kind behind KN069
No study in people, animals or cells on this page reports a result for these. That does not prove KN069 does nothing for them. It does mean anything you have heard about KN069 and one of these did not come from a study cited here.
Show full evidence
What is KN069?
KN069 does the opposite of tirzepatide at the GIP switch, in one molecule, and it also caused weight loss. Half of a dose is still in the body after 37 to 46 days, among the longest of any drug on this site.
Tirzepatide switches on the GIP receptor. This drug blocks it, while switching on GLP-1 in the same molecule. Both cause weight loss in people. If that sounds like it cannot be right, that is the honest state of the field. This drug is the sharpest single example of it.
The first study in people had 48 Chinese men with overweight or obesity. Weight fell more at higher doses. A single 90 mg dose cut weight by 4.71 percent at day 7, against 0.41 percent on a dummy. The effect lasted up to 133 days. That long effect comes from how slowly the body clears it. Half the drug is still there after roughly 900 to 1,100 hours, which is 37 to 46 days.
A single dose still working four months later is a different kind of drug from a weekly shot. It has a different risk, because there is no way to stop it quickly.
How does KN069 work?
One molecule switches on the GLP-1 receptor and blocks the GIP receptor. The GLP-1 half cuts food intake and improves blood sugar in the usual way. The GIP half blocks a switch that tirzepatide turns on. The reasoning comes from mice: mice without the GIP receptor are protected from weight gain on a fatty diet. The leading idea for why turning GIP on and blocking it can both work is this. Keeping it switched on for a long time may wear the switch out, so it ends up acting blocked. That idea is not proven.
What have studies in people found about KN069?
One first study in people, in 48 men. Weight fell more at higher doses, and the drug stays in the body a very long time. There is no mid-stage trial and no comparison with any other drug.
- 48 people in total: 36 got single doses from 12 to 120 mg, and 12 got repeat doses from 15 to 60 mg.
- Well tolerated. Side effects were mostly mild to moderate stomach and bowel complaints, the usual pattern for GLP-1 drugs.
- Weight change at day 7 after one 90 mg dose: down 4.71 percent, against 0.41 percent on a dummy. The effect lasted up to 133 days.
- The 60 mg repeat dose group was down 2.57 percent at day 25. Waist size fell too, by more than chance would explain.
- Blood markers moved the right way. Fasting blood sugar, triglycerides and uric acid went down. Insulin and C-peptide went up.
- Half the drug was still in the body after 899.74 to 1099.01 hours, roughly 37 to 46 days.
What this does not tell you: 48 men in one country, with single doses and short repeat dosing. Weight was noted along the way, not the main thing the study was built to test. Weight lost by day 7 is largely water and gut contents, not fat. The very long stay in the body is a real safety concern, not a selling point. If a side effect shows up, stopping the drug does not stop it. There is no long term data. The comparison with tirzepatide is about how they work, not something measured. No head to head study exists.
The state of the research
This drug sits inside an open puzzle that runs through this whole family of drugs. Switching on the GIP receptor causes weight loss. That is how tirzepatide works. Blocking the GIP receptor also causes weight loss. That is how maridebart cafraglutide works. Both results come from human trials that compared the drug with a dummy. As of this review, two drugs are in mid-stage trials adding opposite GIP actions to the same base drug, semaglutide. NNC0480-0389 switches the receptor on, and AT673 blocks it. There are ideas about why both work. One is that keeping the switch on for a long time wears it out, so it ends up acting blocked. Another is that the brain and the rest of the body respond differently. None is proven. This site reports the puzzle rather than solving it, because nobody has solved it.
The evidence, in charts
Fig. 1a · how many people
2studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Every source here was published in 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- Engineered dual-activity peptide. No mass asserted; no source loaded states one.
- Half-life
- Under 4.2 daysLong, 1 to 7 days
- Chain length
- None on file
Half-life as stated on file: Roughly 900 to 1,100 hours for total drug, which is 37 to 46 days, measured across the 12 to 90 mg dose range. Among the longest on this site, and the reason a single dose acted for up to 133 days.
No amino acid sequence is on file for KN069, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2026A phase 1, randomised, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of KN069
The first human data look promising, and they come from a very small, very early study. Chinese men with overweight or obesity were given single rising doses, three on the drug for every one on a dummy, plus a smaller repeat-dose group. Side effects were mostly mild stomach and bowel complaints. The drug clears extremely slowly, staying in the body for weeks. At the best single dose, weight was down about 4.7% at day seven against 0.4% on the dummy.
First-in-human in Chinese men with overweight or obesity. Single ascending dose 12 to 120 mg, n = 36, randomised 3:1 active to placebo, plus multiple ascending dose n = 12 escalating 15 to 60 mg. Well tolerated with predominantly mild to moderate gastrointestinal adverse events. Dose-proportional exposure from 12 to 90 mg with a total-drug half-life of 899.74 to 1099.01 hours. Maximum early weight change at day 7 on 90 mg was minus 4.71% against minus 0.41% on placebo, sustained up to 133 days. In the multiple-dose part the 60 mg group reached minus 2.57% at day 25 with a significant fall in waist circumference (p = 0.0446). Fasting glucose, triglycerides and uric acid fell and insulin and C-peptide rose.
- Study in people2026A study of KN069 in participants with overweight or obesity
The registry entry for the study above, and the trial is still running. Suzhou Alphamab expects to enrol 36 people with obesity or overweight, with completion estimated for June 2027. Nothing has been posted there yet. Everything known about KN069 in people comes from the journal report, which covers an early stage of this same programme.
The registry record for the trial above.
Where to buy KN069
No seller we track lists KN069 yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has KN069 been tested in people?
Yes. 0 people given it across 1 completed trial cited here, 0 of which found nothing. KN069 does the opposite of tirzepatide at the GIP switch, in one molecule, and it also caused weight loss. Half of a dose is still in the body after 37 to 46 days, among the longest of any drug on this site.
What is the KN069 dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 0 people given it
Is KN069 FDA-approved?
Investigational. Early safety studies only. Not approved anywhere.
How can blocking GIP work if tirzepatide activates it?
Nobody knows yet, and that is the honest state of the field. Mice without the GIP receptor resist weight gain on a fatty diet, which pushed researchers to try blocking it. Then tirzepatide, which switches the receptor on, became one of the most effective approved weight loss drugs. The leading idea is that keeping the switch on wears it out, so it ends up acting blocked. That would make the two approaches the same thing arriving by different roads. It is only an idea.
Is a 37 to 46 day half-life good?
It cuts both ways, and the downside gets less attention. Convenience and steady levels are real pluses. The problem is that if a person reacts badly, there is no way to remove the drug. Effects last for months after the last dose. For a drug tested in only 48 people so far, that calls for more caution than a weekly shot would need.
Is the 4.71 percent weight loss real?
It is a real measurement. It is also a day 7 measurement after a single dose in a first study. Early weight loss on these drugs is largely water and less food in the gut, not fat. Judge the drug on a body fat result from a larger study, and that does not exist yet.